

Freedom of Information Act Disclosure log - Reply Extract

File reference	W21FOI115
Key words	Patients Treated for Breast Cancer Using Surgery, Radiotherapy or Anti-Cancer Therapy
Date of release	25/06/2021
Attachments	No

You asked

1. How many patients have you treated (using surgery, radiotherapy or any systemic anti-cancer therapy) in the last three months for:

- **Breast cancer (any stage)** = 111 – This includes five or fewer patients with no staging recorded and 19 with stage 0
- **Early breast cancer (both early-stage and locally advanced, inclusive of stages I-IIIc)** = 84
- **Metastatic breast cancer (stage IV)** = Five or fewer patients

Please note we are only able to provide figures for patients that started treatment in the last 3 months (1st March 2021 – 31st May 2021).

2. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Used SACT data 1/3/21 – 31/5/21 and ICD codes C50-C509 (invasive breast), D05-D059 (insitu breast), D24X (benign neoplasm of breast) and D486 (neoplasm of uncertain or unknown behaviour of breast) to identify those patients that have had a cycle prescribed during this time

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) = Five or fewer patients
- Abemaciclib + Fulvestrant = 9
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
Epirubicin = Five or fewer patients
- Atezolizumab +Nab-paclitaxel/Paclitaxel = 0
- Capecitabine as a single agent = 24
- Carboplatin or Cisplatin as a single agent = 0
- Eribulin as a single agent or in combination – Eribulin (single agent) = Five or fewer patients
- Everolimus + Exemestane = 0
- Fluorouracil = 0
- Fulvestrant as a single agent = 0
- Lapatinib = 0
- Neratinib = 8

- Olaparib = 0
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) = 32
- Palbociclib + Fulvestrant = 7
- Pertuzumab + Trastuzumab + Docetaxel = 25
- Platinum (e.g. carboplatin or cisplatin) as a single agent = 0
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) = 13
- Ribociclib + Fulvestrant = Five or fewer patients
- Talazoparib = 0
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent Docetaxel – 27, Paclitaxel = 22
- Trastuzumab as a single agent or in combination = 34
- Trastuzumab emtansine = 11
- **Any other active systemic anti-cancer therapy**
 - Carboplatin & Paclitaxel = 12
 - Cisplatin & Gemcitabine = Five or fewer patients
 - EC = 48
 - Everolimus (single agent) = Five or fewer patients
 - Gemcitabine & Carboplatin = Five or fewer patients
 - Atezolizumab, Paclitaxel & Patasertib (trial) = Five or fewer patients
 - Pertuzumab, Ontruzant, Docetaxel & carboplatin = 19
 - Pertuzumab, Ontruzant & Paclitaxel = Five or fewer patients
 - Phesgo, Docetaxel & Carboplatin = Five or fewer patients
 - Phesgo & Docetaxel = 10
 - Docetaxel & Cyclophosphamide Five or fewer patients
 - Vinorelbine = 6

Legal notes:

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b), unless otherwise specified because it constitutes personal information.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer and banded information that could reveal a number of five or fewer. Figures of five or fewer are considered personally identifiable information. Our approach avoids a breach of the first two Data Protection Act principles and the general right to object to processing, whilst providing you with as much detail as possible. This is in accordance with section 40.-(2)(a) and (b) by virtue of the first and second condition.

Attachments included: No



**University Hospitals
Plymouth**
NHS Trust